Intarcia Presents Compelling 48-week Results for ITCA 650 – Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
ITCA 650, injection-free continuous delivery of GLP-1 therapy,demonstrated significant and sustained reductions in HbA1c and bodyweight over 48 weeks of treatment with a marked reduction in the GIAEs typically associated with this classGlobal…
September 14th, 2011
Posted in
Drug